Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) is 2.38% higher on its value in year-to-date trading and has touched a low of $1.58 and a high of $19.18 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AMLX stock was last observed hovering at around $3.61 in the last trading session, with the day’s gains setting it 0.26%.
Currently trading at $3.87, the stock is 13.44% and 8.79% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.93 million and changing 7.20% at the moment leaves the stock 19.39% off its SMA200. AMLX registered -79.47% loss for a year compared to 6-month gain of 85.17%.
The stock witnessed a 4.88% loss in the last 1 month and extending the period to 3 months gives it a -27.66%, and is 17.99% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.79% over the week and 9.38% over the month.
Amylyx Pharmaceuticals Inc (AMLX) has around 123 employees, a market worth around $342.89M and $87.37M in sales. Profit margin for the company is -345.36%. Distance from 52-week low is 145.71% and -79.82% from its 52-week high. The company has generated returns on investments over the last 12 months (-182.62%).
The EPS is expected to grow by 54.70% this year, but quarterly earnings will post -100.00% year-over-year. Quarterly sales are estimated to shrink -100.00% in year-over-year returns.
Amylyx Pharmaceuticals Inc (AMLX) Top Institutional Holders
The shares outstanding are 68.63M, and float is at 64.38M with Short Float at 5.25%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 4.22 million shares valued at $8.03 million. The investor’s holdings represent 6.2251% of the AMLX Shares outstanding. As of 2024-06-30, the second largest holder is AQR CAPITAL MANAGEMENT LLC with 3.34 million shares valued at $6.35 million to account for 4.9114 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 2.67 million shares representing 3.9345% and valued at over $5.07 million, while GOLDMAN SACHS GROUP INC holds 3.8471 of the shares totaling 2.61 million with a market value of $4.96 million.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
The most recent transaction is an insider sale by Klee Justin B., the company’s Co-Chief Executive Officer. SEC filings show that Klee Justin B. sold 4,595 shares of the company’s common stock on Mar 03 ’25 at a price of $3.15 per share for a total of $14483.0. Following the sale, the insider now owns 3.2 million shares.
Amylyx Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 03 ’25 that Cohen Joshua B (Co-Chief Executive Officer) sold a total of 4,595 shares of the company’s common stock. The trade occurred on Mar 03 ’25 and was made at $3.17 per share for $14549.0. Following the transaction, the insider now directly holds 3.2 million shares of the AMLX stock.
Still, SEC filings show that on Mar 03 ’25, Mazzariello Gina (Chief Legal Officer) disposed off 1,611 shares at an average price of $3.12 for $5022.0. The insider now directly holds 133,310 shares of Amylyx Pharmaceuticals Inc (AMLX).
